CorMedix Inc. is a commercial-stage biopharmaceutical company that develops and markets therapies for life-threatening conditions, with a primary focus on infectious diseases and nephrology. The company's flagship product, DefenCath (a combination of taurolidine and heparin), is an FDA-approved antimicrobial catheter lock solution used to prevent catheter-related bloodstream infections in adult patients with kidney failure undergoing hemodialysis. In 2025, CorMedix expanded its commercial footprint by acquiring Melinta Therapeutics, adding established anti-infective drugs such as MINOCIN, REZZAYO, and VABOMERE to its portfolio. The company operates primarily in the United States, targeting dialysis centers, outpatient clinics, and inpatient hospital settings. Beyond its commercialized products, CorMedix is exploring the use of its taurolidine-based platform for other medical applications, including surgical sutures, meshes, and topical hydrogels.
